1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,690 | 3,030 | 09:53 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.06. | Biohit Oyj: Decisions of the Annual General Meeting of Biohit Oyj | 129 | GlobeNewswire (Europe) | Decisions of the Annual General Meeting of Biohit Oyj
Biohit Oyj Decisions of the Annual General Meeting, June 3, 2026 at 6.00 pm local time (EET)
The Annual General Meeting (AGM) of Biohit Oyj held... ► Artikel lesen | |
| 11.02. | Biohit Oyj: Biohit Group Financial Statement Release 2025 | 212 | GlobeNewswire (Europe) | BIOHIT GROUP FINANCIAL STATEMENT RELEASE 2025 (unaudited)
Biohit Oyj Financial Statement Release 11 February 2026 at 9:30 am local time (EET)
SUMMARY
January-December 2025
Revenue EUR 15.7 million... ► Artikel lesen | |
| 08.12.25 | Biohit Oyj: New Study Shows Normal GastroPanel Result Safely Rules Out Need for Gastroscopy | 211 | GlobeNewswire (Europe) | Biohit Oyj Press Release8 December 2025 at 10:30 a.m. EEST
New Study Shows Normal GastroPanel® Result Safely Rules Out Need for Gastroscopy
Major Cost Savings Possible
A newly published clinical study... ► Artikel lesen | |
| 12.11.25 | Biohit Oyj: Chile's national cancer prevention strategy brings GastroPanel technology into public healthcare | 323 | GlobeNewswire (Europe) | Biohit Oyj Press Release12 November 2025 at 2:00 p.m. EEST
Chile's national cancer prevention strategy brings GastroPanel® technology into public healthcare
The Chilean Ministry of Health has introduced... ► Artikel lesen | |
| BIOHIT Aktie jetzt für 0€ handeln | |||||
| 06.08.25 | Biohit Oyj: Biohit Group Half Year Financial Report 2025 (unaudited) | 273 | GlobeNewswire (Europe) | BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2025 (unaudited)
Biohit Oyj Half Year Financial Report 6 August 2025 at 9:30 am local time (EET)
SUMMARY
January-June 2025
Revenue EUR 7.4 million (EUR 7.4... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 73,52 | 0,00 % | CG Oncology bladder cancer trial results published in Lancet | ||
| RELAY THERAPEUTICS | 18,640 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| DYNE THERAPEUTICS | 25,630 | 0,00 % | Dyne Therapeutics Announces Pricing Of Upsized $375 Million Public Offering | ||
| KYMERA THERAPEUTICS | 110,05 | 0,00 % | Kymera Therapeutics names Terence Rooney as chief medical officer | ||
| TANGO THERAPEUTICS | 26,720 | 0,00 % | How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48% | ||
| VERA THERAPEUTICS | 35,180 | 0,00 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 52,74 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 60,12 | 0,00 % | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 | ||
| ZENAS BIOPHARMA | 32,820 | 0,00 % | Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | - BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (Nasdaq:... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,010 | 0,00 % | Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 | ||
| APOGEE THERAPEUTICS | 134,31 | +0,02 % | Apogee Therapeutics Aktie erreicht Rekordhoch von 134,34 USD | ||
| PRAXIS PRECISION MEDICINES | 316,02 | +0,07 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| TYRA BIOSCIENCES | 31,060 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| ERASCA | 18,890 | +0,11 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 30,160 | 0,00 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports First Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent... ► Artikel lesen |
Das Unternehmen BIOHIT OYJ kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,860 Euro und damit 0,00 % im Plus. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOHIT OYJ finden Sie auf Wallstreet Online.